EUVIMEDEUVIMED entdecken
Vergleichsstudie

Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration

Kristen Wilhite iD, Jennifer Meyer Reid, Matthew Lane

Annals of Pharmacotherapy · 2024

DOI: 10.1177/10600280231205490 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Kristen Wilhite und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Veterans Affairs Medical Center, Louisville, KY, USA. Hauptthemen laut MEDLINE: Pancreatitis, Diabetes Mellitus, Type 2, Thiazolidinediones, Incretins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Incretin therapies, comprised of the dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have been increasingly utilized for the treatment of type 2 diabetes (T2DM). Previous studies have conflicting results regarding risk of pancreatitis associated with these agents—some suggest an increased risk and others find no correlation. Adverse event reporting systems indicate that incretin therapies are some of the most common drugs associated with reports of pancreatitis.

Objectives

This study aimed to compare the odds of developing pancreatitis in veterans with T2DM prescribed an incretin therapy versus thiazolidinediones (TZDs: pioglitazone and rosiglitazone) within the Veterans Health Administration (VHA).

Methods

This was a retrospective cohort study analyzing veterans with T2DM first prescribed an incretin therapy or a TZD between January 1, 2011, and December 31, 2021. A diagnosis of pancreatitis within 365 days of being prescribed either therapy was counted as a positive case. Data was collected and analyzed utilizing VA’s Informatics and Computing Infrastructure (VINCI) and an adjusted odds ratio was calculated.

Results

The TZD cohort consisted of 42 912 patients compared with the incretin cohort of 304 811 patients. The TZD cohort had a pancreatitis incidence rate of 1.94 cases per 1000 patients. The incretin cohort had a incidence rate of 2.06 cases per 1000 patients. An adjusted odds ratio found no statistical difference of pancreatitis cases between the TZD and incretin cohorts (adjusted odds ratio [AOR] = 0.94, 95% CI [0.75, 1.18]). Conclusion and Relevance: This retrospective cohort study of national VHA data found a relatively low incidence of pancreatitis in both cohorts, and an adjusted odds ratio found no statistical difference of pancreatitis in patients prescribed an incretin therapy compared with a control group. This data adds to growing evidence that incretin therapies do not seem to be associated with an increased risk of developing pancreatitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PancreatitisDiabetes Mellitus, Type 2ThiazolidinedionesIncretinsHypoglycemic AgentsUnited States Department of Veterans AffairsHumansRetrospective StudiesMaleMiddle AgedFemaleUnited StatesAgedDipeptidyl-Peptidase IV InhibitorsCohort StudiesPioglitazoneVeteransRosiglitazoneGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

diabetesdipeptidyl peptidase-4 inhibitorglucagon-like peptide 1 agonistincretinpancreaspancreatitisthiazolidinedioneveterans affairs

Substanzen

ThiazolidinedionesIncretinsHypoglycemic AgentsDipeptidyl-Peptidase IV InhibitorsPioglitazoneRosiglitazoneGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Pharmacy, Veterans Affairs Medical Center, Louisville, KY, USA.
  • Department of Pharmacy, Veterans Affairs Health Care System, Lexington, KY, USA.

ORCID-Profile: Kristen Wilhite

Zitieren

APA

Wilhite, K., Reid, J. M., & Lane, M. (2024). Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231205490

Vancouver

Wilhite K, Reid JM, Lane M. Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280231205490

BibTeX
@article{Wilhite2024,
  author = {Wilhite, Kristen and Reid, Jennifer Meyer and Lane, Matthew},
  title = {Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration},
  journal = {Annals of Pharmacotherapy},
  year = {2024},
  doi = {10.1177/10600280231205490}
}
Kostenlos starten →